Background Despite high vaccine coverage and effectiveness, the incidence of symptomatic
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

Background Despite the high efficacy of the BNT162b2 messenger RNA vaccine against
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough infections …

A Fourth Dose of mRNA Vaccine in Health Care Workers Health care workers in Israel were
given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant …

Background Concurrent with the Pfizer–BioNTech BNT162b2 COVID-19 vaccine roll-out in
Israel initiated on Dec 19, 2020, we assessed the early antibody responses and antibody …

Importance The BNT162b2 two-dose vaccine (BioNTech/Pfizer) has high effectiveness that
wanes within several months. The third dose is effective in mounting a significant immune …

Objectives The immunogenicity and safety of the Pfizer-BioNTech BNT162b2 mRNA vaccine
in people living with human immunodeficiency virus type 1 (PLWH) are unknown. We …

Follow-up after a Fourth BNT162b2 Vaccine Dose Although a third vaccine dose showed an
improved and sustained level of protection as compared with a second dose, the …

The COVID-19 pandemic and the fast global spread of the disease resulted in unprecedented
decline in world trade and travel. A critical priority is, therefore, to quickly develop …

As the effectiveness of a two-dose messenger RNA (mRNA) severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) vaccine regimen decreases with time, a third dose has …

Background An Israeli national taskforce performed a multi-center clinical and analytical
validation of seven serology assays to determine their utility and limitations for SARS-CoV-2 …